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Abstract 
 
Background Simple bleeding risk scores have been proposed to predict bleeding events, in 
patients anticoagulated using non-warfarin anticoagulants.  We compared the relative 
predictive values of two bleeding risk scores, HAS-BLED and ORBIT, in non-warfarin 
anticoagulated patients with atrial fibrillation (AF). 
Methods and Results   In a post-hoc ancillary analysis of ‘clinically relevant bleeding’ events 
amongst 2283 patients in the idraparinux arm in the AMADEUS trial. The two scores 
performed modestly in predicting both bleeding outcomes, although there was a trend for 
better HAS-BLED score performance in predicting any clinically relevant bleeding [c-indexes 
in HAS-BLED vs. ORBIT; 0.61 (95%CI; 0.58-0.64) vs. 0.58 (95%CI; 0.55-0.61); c-index 
difference = 0.03, z-score = 1.84, p = 0.06).  Using the HAS-BLED score compared with the 
ORBIT score correctly and significantly reclassified 15.6% of the population (95% CI: 4.3 to 
27.0; p = 0.007).   Decision curve analyses confirmed the increasing ability to correctly 
identify patients who would bleed using the HAS-BLED score versus the ORBIT score, over a 
wide range of thresholds for any clinically relevant bleeding risk predictions.   
Conclusion  In this comparison of the HAS-BLED and ORBIT scores in a cohort of non-
warfarin anticoagulated patients with AF, we show that the HAS-BLED score more accurately 
predicted any clinically relevant bleeding amongst patients with AF who were 
anticoagulated with a non-warfarin anticoagulant, when compared with the ORBIT score.  
 
Key words:  bleeding risk, HAS-BLED score, ORBIT score, atrial fibrillation, idraparinux   
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 3 
Introduction 
 
Assessment of bleeding risk is important in the management of patients with atrial 
fibrillation (AF). Two bleeding risk scores, the HAS-BLED [Hypertension, Abnormal renal/liver 
function, Stroke, Bleeding history, Labile international normalized ratio (INR), Elderly 
(age≥65 years), Drugs or alcohol concomitant] and ORBIT [Older age (≥ 74 years), Reduced 
hemoglobin/anemia (hemoglobin <13 g/dl in men and <12 g/dl in women or hematocrit 
<40% for males and <36% for females) (2 points), Bleeding history (2 points), Insufficient 
kidney function (glomerular filtration rate <60 ml/min/1.73m2), Treatment with 
Antiplatelet] scores, have been derived and validated in AF populations, with the ORBIT 
score being proposed as a simple score that can be applied in AF patients on any 
anticoagulant (ie. whether using warfarin or non-warfarin anticoagulants) by not 
considering the ‘labile INR’ criterion that applies for warfarin users with the HAS-BLED 
score.1,2   Of note, the L (labile INR) criterion in HAS-BLED is only applicable in a warfarin 
user, otherwise this criterion scores zero. 
 
In the present analysis, these 2 bleeding scores were tested for their predictive abilities for 
clinically relevant bleeding amongst patients randomised to the idraparinux arm (ie. a non-
warfarin anticoagulant) of the AMADEUS trial (Evaluating the Use of SR34006 Compared to 
Warfarin or Acenocoumarol in Patients With Atrial Fibrillation) 3.  
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Methods  
 
The AMADEUS trial design has previously been described 3. The incidence of outcomes, any 
clinically relevant bleeding (the centrally adjudicated primary safety endpoint) are 
expressed as counts and/or percentages. 
 
Discrimination and clinical usefulness were assessed for the HAS-BLED and the ORBIT score. 
Discrimination was studied with the concordance (c) index, which is identical to the area 
under the receiver-operating characteristic (ROC) curve, and Net reclassification 
improvement (NRI)4.  As originally proposed, the NRI seeks to quantify whether a new 
marker provides clinically relevant improvements in prediction and has recently become a 
popular measure of incremental usefulness of markers added to risk prediction models. 5 
Thus, to avoid confusion and biases that categorization of the data can cause, we calculated 
NRI for continues scores.  
 
Clinical usefulness was assessed using decision curve analyses (DCA)6. This analysis 
estimates a “net benefit” for a prediction model that provides individual risk estimate.  The 
DCA demonstrates identification of patients who will have any clinically relevant bleeding, 
based on the predictions of one risk score, compared with another score.  On the DCA, the 
x-axis shows threshold values for any clinically relevant bleeding risk. The clinician may use 
the threshold to classify patients as high or low risk at a value to proceed with some action, 
such as increased patient monitoring or additional medical therapy. The y-axis represents 
the net benefit for the different threshold values of any clinically relevant bleeding risk. Thus, 
the interpretation of the net benefit is in units of true positives and represents the sum of 
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how many patients are correctly identified to be ‘high risk’ (true positive: i.e., bleeding) 
minus a weighted number of patients incorrectly identified as high risk (false positive: i.e., 
none bleed).   We plotted a slanted grey line which represents the classification of all 
patients as high risk (i.e., bleed); and a horizontal line representing the classification of all 
patients as low risk (i.e., none bleed), with the latter resulting in a net benefit of 0.  The 
prediction models that are the farthest away from the slanted grey line (i.e., assume all 
bleed) and the horizontal line (i.e., assume none bleed) demonstrates the higher net benefit.  
Statistical analyses were performed with R software 7 and SPSS (version 21.0). 
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Results  
A total of 2,283 patients (mean age ± standard deviation [SD]; 70.1 ± 9.0 years) in AMADEUS 
were randomized to the idraparinux arm. Overall, 74 major bleeding events and 346 
clinically relevant bleeding events occurred during the follow-up period (311 ± 161 days). 
Specific bleeding data for each risk score are shown in Table 1. 
 
There was modest discriminative ability for any clinically relevant bleeding, as reflected by 
the c-indexes in ROC curve analysis; c-indexes of 0.61 in HAS-BLED score (95% confidence 
interval [CI]: 0.58 to 0.64, p<0.001) and 0.58 in ORBIT score (95% CI: 0.55 to 0.61, P<0.001) 
[Figure 1].  Comparison of c-indexes revealed a non-significant trend for better 
discriminative ability of the 2 tested scores for any clinically relevant bleeding (HAS-BLED vs. 
ORBIT, c-index difference 0.03, z-score = 1.84, p = 0.06).  For the secondary outcome of 
major bleeding, c-indexes for the HAS-BLED score was 0.59 (95% CI: 0.53 to 0. 65, P=0.007) 
and ORBIT score, 0.58 (95% CI: 0.52 to 0.65, P=0.014), with no significant difference 
between the two scores (c-index difference 0.01, z-score = 0.27, p = 0.79).  
 
For the primary outcome of any clinically relevant bleeding, using the HAS-BLED score 
compared with the ORBIT score correctly (and significantly) reclassified 15.6% of the 
population (95% CI: 4.3 to 27.0; p = 0.007). For the secondary outcome of major bleeding, 
using the HAS-BLED score compared with the ORBIT score non-significantly reclassified -
3.7% (95% CI: -26.5 to 19.2; p = 0.753) of the population. 
 
The decision-curve analysis (DCA) demonstrated identification of patients who will have any 
clinically relevant bleeding, based on the predictions of HAS-BLED score, compared with 
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ORBIT score (Figure 2).   The intersection of the y-axis and the slanted grey line represents 
the overall risk of any clinically relevant bleeding (15%).  Being farthest away from the 
slanted grey line (i.e., assume all bleed) and the horizontal line (i.e., assume none bleed), 
the HAS-BLED score (broken red line) demonstrates the higher net benefit, followed by the 
ORBIT score (broken black line).  Thus, the HAS-BLED score outperformed the ORBIT using 
DCA, over a wide range of thresholds probability for any clinically relevant bleeding.  
 
In a Cox regression analysis, both HAS-BLED score ≥3 (i.e., high risk category) and ORBIT 
score ≥3 (i.e. high risk category) were predictors of any clinically relevant bleeding with 
hazard ratios of 2.2 (95% CI: 1.6 to 3.0; p<0.001) and 1.7 (95% CI: 1.2 to 2.4; p =0.001) (vs. 
low-risk category as baseline risk), respectively.   
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Discussion 
 
In this comparison of the HAS-BLED and ORBIT scores in a cohort of non-warfarin 
anticoagulated patients with AF, we show that the HAS-BLED score more accurately 
predicted any clinically relevant bleeding amongst patients with AF who were 
anticoagulated with a non-warfarin anticoagulant, when compared with the ORBIT score.  
Indeed, the HAS-BLED score demonstrated greater discriminative performance as reflected 
by the NRI and c-index, and its clinical usefulness reflected by DCA when compared with 
ORBIT score for the adjudicated outcome of any clinically relevant bleeding. 
 
Clinically relevant bleeding was the centrally adjudicated primary safety endpoint in the 
AMADEUS trial and would be clinically meaningful and highly relevant to patients who are at 
risk of important bleeding events in daily clinical practice. The modest predictive 
performance of the scores for ‘high risk’ patients sustaining events should be put into 
context of the relatively ‘low risk’ clinical trial population studied (approx. 90% were ‘low 
risk’).  Also, notable differences between HASBLED and ORBIT include the different weighing 
for bleeding tendency or predisposition in the ORBIT score, as well as the lack of 
consideration of uncontrolled hypertension, abnormal liver function, prior stroke, 
concomitant use of NSAIDs and labile INRs (for a warfarin user).   All these parameters are 
included in HASBLED, and allow physicians to consider more bleeding risk factors, and draw 
attention to those that are reversible or correctable.   
 
However, the principal objective of this ancillary analysis was to assess how these 2 bleeding 
scores perform with non-warfarin anticoagulants.  Notwithstanding the fact that the 
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development of idraparinux has ceased, this analysis is still relevant as ORBIT was 
introduced as a score that would be ‘better’ even when used for non-warfarin 
anticoagulants2 – instead, our results suggest the opposite.  Thus, further studies are 
needed to investigate that these scores in a broader spectrum of patients at high bleeding 
risk, in real-world clinical practice. 
 
These results are in accordance with prior results from the warfarin arm of the AMADEUS 
cohort8, suggesting that despite some initial validations in warfarin-treated populations, the 
HAS-BLED and ORBIT schemes maintain their modest predictive performance in patients 
receiving other (non-warfarin) forms of anticoagulation.   In the warfarin arm of the 
AMADEUS cohort8, there was a significant improvement in ORBIT score prediction 
performance by considering time in therapeutic range as a measure of ‘labile INR’ (a 
criterion included within the HAS-BLED score, but not ORBIT).   Similar findings were 
reported by Proietti et al9, where the ORBIT score categorised a large proportion of AF 
patients who has sustained major bleeding on warfarin as being ‘low risk’, and that the 
predictive performance of the ORBIT score could be significantly improved by adding ‘poor 
TTR’ (or labile INR) as an added criterion.  Based on these observations, the HAS-BLED score 
performs better than the ORBIT score for the outcome of any clinically relevant bleeding, 
whether using warfarin or non-warfarin anticoagulants.   
 
Why use bleeding risk scores?   These scores can help identify patients with common risk 
factors for bleeding, so in the case of HASBLED, would ‘flag up’ those patients potentially at 
risk of bleeding for more careful review and medical follow-up, and to draw attention to 
potentially reversible/ correctable bleeding risk factors11. Of note, bleeding risk scores 
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should not be used as an excuse to withhold oral anticoagulation, as such AF patients would 
derive even greater net clinical benefit from stroke prevention9.  Rather than a focus on 
absolute bleeding rates, bleeding risk scores could facilitate clinical or electronic alerts to 
‘flag up’ high risk patients, and to alert the clinician to address potentially modifiable 
bleeding risk factors11-13.   Addressing the latter may minimise the risks of bleeding from 
antithrombotic therapy, and is an approach recommended in contemporary guidelines12.  
Indeed, the HAS-BLED score clearly fulfils this role, in contrast to other simple risk scores13.   
 
Limitations 
It is difficult to fully claim that one score is definitely better than another one, given the 
various ways of assessing differences in predictive value. The results of comparisons 
between the two scores in the present study were statistically significant based on the NRI 
and DCA. Thus, we suggest that the HAS-BLED score is statistically better at predicting any 
clinical relevant bleeding than the ORBIT score, although both scores had modest prediction 
performance using the ROC analysis.  Of note, the latter is now regarded to be insufficient 
alone when assessing predictive value, and should be supplemented with the NRI and - 
more recently - the DCA approaches4-6.  All clinical factor-based risk scores in various clinical 
settings (eg. CHADS2, CHA2DS2VASc, Killip, TIMI etc) show broadly similar c-indexes (approx. 
0.6) when used to predict those categorised at ‘high risk’ who actually sustain events11.   
Again, HAS-BLED offers simplicity and draws attention to the potentially reversible risk 
factors for bleeding – as recommended in guidelines11,12.    Finally, HASBLED and ORBIT are 
bleeding risk scores derived and validated in patients with AF – and used to predict those 
patients potentially at high risk of bleeding and (with HAS-BLED) to draw attention to the 
reversible risk factors for bleeding.  Both score are not used to define ‘bleeding severity’ 
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after the bleeding event (eg. TIMI, GUSTO or BARC - which were also derived/validated in 
non-AF patients).     
 
In conclusion, when compared with the ORBIT score, the HAS-BLED score more accurately 
predicted individuals with any clinically relevant bleeding in patients with AF who were 
anticoagulated with a non-warfarin anticoagulant.   Given its simplicity, the HAS-BLED score 
should be recommended for bleeding risk assessment, whether using warfarin or non-
warfarin anticoagulants.  
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FIGURE LEGENDS 
 
Figure 1  Receiver-operating characteristic (ROC) curves for any clinically relevant bleeding  
with the HAS-BLED and ORBIT scores  
 
Figure 2 Decision Curves demonstrating identification of patients who will have any 
clinically relevant bleeding, based on the predictions of HAS-BLED score, compared with 
ORBIT score 
The x-axis shows threshold values for any clinically relevant bleeding risk. The y-axis 
represents the net benefit for the different threshold values of any clinically relevant 
bleeding risk.  
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Table 1   Bleeding events in the AMADEUS trial population stratified according to the 
HAS-BLED and ORBIT bleeding risk scores 
  Any clinically 
relevant bleeding 
Major bleeding 
 N N (%) N (%) 
HAS-BLED    
0 364 30 (8.2) 3 (0.8) 
1 1139 144 (12.6) 38 (3.3) 
2 633 132 (20.9) 25 (3.9) 
3 131 34 (26.0) 8 (6.1) 
4 7 5 (71.4) 0 (0) 
    
ORBIT    
0 845 92 (10.9) 19 (2.2) 
1 975 156 (16.0) 33 (3.4) 
2 286 57 (19.9) 10 (3.5) 
3 147 30 (20.4) 8 (5.4) 
4 29 11 (37.9) 4 (13.8) 
5 1 0 (0) 0 (0) 
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HAS-BLED score= Hypertension, Abnormal renal/liver function, Stroke, Bleeding 
history, Labile international normalized ratio (INR), Elderly (age≥65 years), drugs or 
alcohol concomitant 
ORBIT score=  Older age (≥ 74 years), reduced hemoglibin/Anemia [(hemoglobin <13 
g/dl in men and <12 g/dl in women) or (hematocrit <40% for males and <36% for 
females) (2 points)], Bleeding history (2 points), Insufficient kidney function 
[glomerular filtration rate <60 ml/min/1.73m2], Treatment with Antiplatelet. 
